Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.

نویسندگان

  • Jackie Bosch
  • John W Eikelboom
  • Stuart J Connolly
  • Nancy Cook Bruns
  • Vivian Lanius
  • Fei Yuan
  • Frank Misselwitz
  • Edmond Chen
  • Rafael Diaz
  • Marco Alings
  • Eva M Lonn
  • Petr Widimsky
  • Masatsugu Hori
  • Alvaro Avezum
  • Leopoldo S Piegas
  • Deepak L Bhatt
  • Kelley R H Branch
  • Jeffrey L Probstfield
  • Yan Liang
  • Lisheng Liu
  • Jun Zhu
  • Aldo P Maggioni
  • Patricio Lopez-Jaramillo
  • Martin O'Donnell
  • Keith A A Fox
  • Ajay Kakkar
  • Alexander N Parkhomenko
  • Georg Ertl
  • Stefan Störk
  • Katalin Keltai
  • Matyas Keltai
  • Lars Ryden
  • Gilles R Dagenais
  • Nana Pogosova
  • Antonio L Dans
  • Fernando Lanas
  • Patrick J Commerford
  • Christian Torp-Pedersen
  • Tomasz J Guzik
  • Peter B Verhamme
  • Dragos Vinereanu
  • Jae-Hyung Kim
  • Jong-Won Ha
  • Andrew M Tonkin
  • John D Varigos
  • Basil S Lewis
  • Camilo Felix
  • Khalid Yusoff
  • Philippe Gabriel Steg
  • Victor Aboyans
  • Kaj P Metsarinne
  • Sonia S Anand
  • Robert G Hart
  • Andre Lamy
  • Paul Moayyedi
  • Darryl P Leong
  • Mukul Sharma
  • Salim Yusuf
چکیده

BACKGROUND Long-term aspirin prevents vascular events but is only modestly effective. Rivaroxaban alone or in combination with aspirin might be more effective than aspirin alone for vascular prevention in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD). Rivaroxaban as well as aspirin increase upper gastrointestinal (GI) bleeding and this might be prevented by proton pump inhibitor therapy. METHODS Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) is a double-blind superiority trial comparing rivaroxaban 2.5 mg twice daily combined with aspirin 100 mg once daily or rivaroxaban 5 mg twice daily vs aspirin 100 mg once daily for prevention of myocardial infarction, stroke, or cardiovascular death in patients with stable CAD or PAD. Patients not taking a proton pump inhibitor were also randomized, using a partial factorial design, to pantoprazole 40 mg once daily or placebo. The trial was designed to have at least 90% power to detect a 20% reduction in each of the rivaroxaban treatment arms compared with aspirin and to detect a 50% reduction in upper GI complications with pantoprazole compared with placebo. RESULTS Between February 2013 and May 2016, we recruited 27,395 participants from 602 centres in 33 countries; 17,598 participants were included in the pantoprazole vs placebo comparison. At baseline, the mean age was 68.2 years, 22.0% were female, 90.6% had CAD, and 27.3% had PAD. CONCLUSIONS COMPASS will provide information on the efficacy and safety of rivaroxaban, alone or in combination with aspirin, in the long-term management of patients with stable CAD or PAD, and on the efficacy and safety of pantoprazole in preventing upper GI complications in patients receiving antithrombotic therapy.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).

BACKGROUND High blood pressure is an important public health concern because it is highly prevalent and a risk factor for adverse health outcomes, including coronary heart disease, stroke, decompensated heart failure, chronic kidney disease, and decline in cognitive function. Observational studies show a progressive increase in risk associated with blood pressure above 115/75 mm Hg. Prior resea...

متن کامل

Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial

BACKGROUND Previous large trials of vitamin D for prevention of fractures and other disease outcomes have reported conflicting results, possibly because the doses tested were insufficient to maintain optimum blood levels of vitamin D (25[OH]D) predicted by the observational studies. This report describes the design and baseline characteristics of the BEST-D (Biochemical Efficacy and Safety Tria...

متن کامل

Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk

BACKGROUND The Kanyini Guidelines Adherence with the Polypill (Kanyini-GAP) Study aims to examine whether a polypill-based strategy (using a single capsule containing aspirin, a statin and two blood pressure-lowering agents) amongst Indigenous and non-Indigenous people at high risk of experiencing a cardiovascular event will improve adherence to guideline-indicated therapies, and lower blood pr...

متن کامل

A Nutrition Education Intervention Trial for Adolescent Girls in Isfahan: Study Design and Protocol

BackgroundNutrition behaviors of adolescent girls is of serious health concerns. Although nutrition education interventions in Iran have met with some success, most of them could not promote nutrition behavioral changes. The aim of our study is to determine a school-based nutrition education intervention to improve adolescents’ nutrition behaviors and behavioral mediators based on the social co...

متن کامل

An innovative team-based weightloss competition to reduce cardiovascular and diabetes risk among Māori and Pacific people: rationale and method for the study and its evaluation

Background: Obesity rates for New Zealand (NZ) Pacific and Māori (NZ indigenous people) are among the highest in the world. Long-term results of weight management programmes for adults have been modest but primarily focused on individuals. This paper describes the rationale and methodology for a trial of a culturally tailored team-based weightloss competition conducted online with community lev...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • The Canadian journal of cardiology

دوره 33 8  شماره 

صفحات  -

تاریخ انتشار 2017